Tantivy Sciences, a wholly-owned subsidiary of Digital Bridge Inc. (OTCBB:DGBI) today announced the execution of an exclusive distribution license with V-Tech LLC, a California biomedical company that develops medical foods, dietary supplements, and pharmaceutical applications to non-drug products.
V-Tech has granted Tantivy Sciences an exclusive license to two products: Vasodyne and Natural Smokeless. Vasodyne, the newest product licensed by Tantivy Sciences, is designed to raise facial temperature to provide increased blood flow by increasing the brain chemical nitric oxide. Clinical trials have demonstrated that the increased facial blood flow brought about by the Vasodyne product provides several benefits, including reducing wrinkles and improving age-related skin damage.
In August 2001, Tantivy Sciences (F.K.A. DB Capital Management) licensed Natural Smokeless. Natural Smokeless is a unique dietary supplement that increases the synthesis of neurotransmitters that are depleted by nicotine. It is designed to suppress nicotine cravings, and thus help smokers reduce the number of cigarettes they smoke. Clinical trials have established a significant reduction in nicotine cravings in smokers who used Natural Smokeless, which resulted in fewer cigarettes smoked. The Natural Smokeless product was formerly licensed through a joint venture, which was discontinued by Tantivy Sciences in favor of a direct licensing arrangement.
"This product license truly exemplifies what Tantivy Sciences is all about," stated Tantivy Sciences Managing Director Ron Friedman. "We are obtaining exclusive rights distribute truly unique and exciting products, and introducing them to the $49 billion U.S. nutrition industry. We are only interested in the highest quality products, backed by significant research and proven clinical studies. V-Tech is a perfect partner for us, as the science behind their products is second to none."
The V-Tech products were developed using a proprietary process, known as "targeted cellular technology," which allows certain amino acids to target and enter nerve, brain and muscle cells in order to selectively produce neurotransmitters without pharmacological tolerance. Several proprietary products have been developed through this patented process, all of which directly affect specific neurotransmitter functions. Neurotransmitters control all of the automatic functions of the body, including heart rate, breathing, mood, sleep, temperature, memory, mental acuity, and muscle strength.
About Tantivy Sciences Inc.
Tantivy Sciences is a comprehensive nutraceutical and pharmaceutical development, distribution and management company that manufactures and distributes ground-breaking nutraceutical products through retail, wholesale, direct marketing, and online channels, and also offers a beginning-to-end manufacturing and distribution solution to physicians and other scientists who have developed new and unique health-related nutritional products. No other company can lay claim to such a powerful and effective product line, comprised of proprietary nutritional formulas designed by respected physicians, and backed by rigorous scientific research and clinical studies.
About V-Tech LLC
V-Tech is a biomedical company in the business of developing medical foods, dietary supplements, and pharmaceutical applications to non-drug products. The company's principal business objectives are: (1) the development and commercialization of proprietary non-drug medical foods sold through participating physicians in the United States; (2) the international licensing and commercialization of proprietary non-drug medical foods and dietary supplements into direct consumer and mass consumer markets; and (3) the licensing of intellectual property rights to major pharmaceutical companies.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the company's future expectations, including future revenues and earnings, the anticipated stock dividends and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.